NCT00296192View on ClinicalTrials.gov

Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms

PHASE2CompletedINTERVENTIONAL

Enrollment

82

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions

Parkinson's Disease

Interventions

DRUG

Rotigotine nasal spray

Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries

OTHER

Placebo

placebo nasal spray 1, 2 3, and 4 puffs

Sponsors

Lead Sponsor

All Listed Sponsors

lead

UCB Pharma

INDUSTRY